Scientists have created a drug that kills the breast cancer cells

American scientists have developed a nanopreparation, which directly affects the aggressive cancer cells in the breast, killing them without toxic side effects. It is effective against the most complex shape — triple negative breast cancer. The study is published in the journal of Advanced Therapeutics.

Triple negative breast cancer — the most aggressive and deadly form of cancer of the breast. It does not contain any one of three types of proteins-receptors — estrogen, progesterone and epidermal growth factor person of the second type. This means that it cannot be treated using a receptor-oriented therapy. Doesn't always work and chemo, as the cancer rapidly develops metastases throughout the body, and often requires surgical intervention.

Scientists from the University of Arkansas, led by associate Professor of chemistry and biochemistry Beyzavi Hassan (Hassan Beyzavi) has developed a new nanopreparations that kills the cells three times negative breast cancer.

In chemical structure the drug belongs to a new class of nanomaterials called metal-organic frameworks with ligands. Ligands are molecules that are associated with other molecules via donor-acceptor interaction.

The drug is intended for targeted drug delivery in the process of photodynamic therapy. Laboratory Beyzavi for several years engaged in the development of methods of photodynamic therapy (PDT) as a safer alternative to chemotherapy and surgery.

The method is based on non-invasive approach based on the use of substances-photosensitizers which upon irradiation with light to generate reactive oxygen species that kill cancer cells without creating toxicity for normal cells. This method has much less side effects compared to chemotherapy.

"Thousands of women die from breast cancer each year, presented in a press release of the University of the word Basavi. — Patients with triple-negative cells are especially vulnerable because of the toxic side effects of the only approved treatment of this type of cancer — chemotherapy. We solved this problem by developing a composition that targets cancerous cells and has no effect on healthy cells."

Scientists have created a nanoporous metal-organic framework, specifically aimed at tumor cells, significantly increases the efficiency of PDT.

The researchers also studied the options of integrated application of new systems of drug delivery with magnetic resonance imaging (MRI) and fluorescence imaging, by which it is possible to track the movement of drugs in the body and to monitor the progress of treatment.

The authors believe their method will allow to refuse the chemotherapy which to date are 80% of patients with triple negative breast cancer, which uses highly toxic drugs — doxorubicin and anthracyclines, which negatively acts on the heart and has many other serious side effects.